BLRX Stock Overview
A commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BioLineRx Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.15 |
| 52 Week High | ₪0.70 |
| 52 Week Low | ₪0.15 |
| Beta | 0.93 |
| 11 Month Change | -18.03% |
| 3 Month Change | -30.23% |
| 1 Year Change | -62.41% |
| 33 Year Change | -78.13% |
| 5 Year Change | -86.63% |
| Change since IPO | -99.77% |
Recent News & Updates
Recent updates
Does BioLineRx (TLV:BLRX) Have A Healthy Balance Sheet?
Apr 02
BioLineRx (TLV:BLRX) Has Debt But No Earnings; Should You Worry?
Aug 25Health Check: How Prudently Does BioLineRx (TLV:BLRX) Use Debt?
Apr 05Is BioLineRx (TLV:BLRX) A Risky Investment?
Jun 17Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?
Feb 26Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?
Oct 17Shareholder Returns
| BLRX | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | -2.0% | 4.4% | 2.5% |
| 1Y | -62.4% | -10.8% | -1.2% |
Return vs Industry: BLRX underperformed the IL Biotechs industry which returned -10.8% over the past year.
Return vs Market: BLRX underperformed the IL Market which returned -1.2% over the past year.
Price Volatility
| BLRX volatility | |
|---|---|
| BLRX Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IL Market | 7.8% |
| 10% least volatile stocks in IL Market | 3.1% |
Stable Share Price: BLRX's share price has been volatile over the past 3 months.
Volatility Over Time: BLRX's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 79 | Phil Serlin | www.biolinerx.com |
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions.
BioLineRx Ltd. Fundamentals Summary
| BLRX fundamental statistics | |
|---|---|
| Market cap | ₪179.86m |
| Earnings (TTM) | -₪183.57m |
| Revenue (TTM) | ₪43.53m |
4.1x
P/S Ratio-1.0x
P/E RatioIs BLRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLRX income statement (TTM) | |
|---|---|
| Revenue | US$11.66m |
| Cost of Revenue | US$5.15m |
| Gross Profit | US$6.51m |
| Other Expenses | US$55.66m |
| Earnings | -US$49.15m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.041 |
| Gross Margin | 55.84% |
| Net Profit Margin | -421.69% |
| Debt/Equity Ratio | 73.6% |
How did BLRX perform over the long term?
See historical performance and comparison